The funds will be used to progress the clinical development and assessment of the company’s minimally invasive ultrasound-based catheter to treat pulmonary hypertension. Credit: Bits And Splits / Shutterstock.com.

France-based medical device company Gradient Denervation Technologies has secured €14m ($15m) in a Series A funding round to advance the clinical development of its ultrasound-based catheter device.

The financing round was led by venture capital company Asabys Partners through its new fund, Sabadell Asabys II, with Thuja Capital and founding investor Sofinnova Partners taking part.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Gradient also plans to use the investment to progress the assessment of its catheter to treat pulmonary hypertension.

In the initial stage, the catheter will be developed for the Group 2 population, or people with heart failure with associated high pulmonary vascular resistance.

A minimally invasive device, the ultrasound-based catheter can be used in the pulmonary arteries and leverages therapeutic ultrasound energy to carry out the denervation procedure.

See Also:

Established in 2020, Gradient received seed funds worth €3.5m from Sofinnova MD Start, a medtech accelerator of venture capital corporation Sofinnova Partners.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company launched the first-in-human clinical trial of the device, enrolling the first subject in June 2023.

Gradient Denervation Technologies CEO Martin Grasse said: “I’m very happy to welcome Asabys Partners and Thuja Capital to the Gradient team.

“In addition to capital, these investors bring deep expertise and thought partnership to Gradient as we seek to bring our technology to patients.”